Advantage in overall survival, but disadvantage in severe side effectsRegorafenib (trade name: Stivarga) has been approved in Germany since August 2013 for adults with metastatic colorectal cancer in whom previous treatments are no longer effective or for whom these alternatives are not an option.
No comments:
Post a Comment